Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer
Astellas Pharma is conducting a double-blind study to evaluate ASP2138 in combination with chemotherapy and pembrolizumab for patients with HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction cancer.
Phase III
Oncology / Gastric Cancer
Status
Negative
Sponsor
Astellas Pharma
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The initiation of the ASP2138 trial represents a significant opportunity for Astellas Pharma to enhance its oncology portfolio, particularly in the HER2-negative gastric cancer segment. Success in this trial could provide a competitive edge against existing therapies and improve treatment options for a challenging patient population.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety, particularly progression-free survival rates compared to placebo, as well as any updates on patient recruitment and interim analyses.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.